FDA Investigator: Emmanuel Adu-Gyamfi
- Emmanuel Adu-Gyamfi first started conducting FDA inspections in 2022, with the last inspection in 2023. Over that time, Emmanuel Adu-Gyamfi has conducted 5 inspections at 5 companies across 5 sites.
Get Emmanuel Adu-Gyamfi's official FDA inspection documents. Gain valuable insights from their Form 483s and EIRs to ace your next inspection.
Documents
Upon purchase, you will receive an email with a link to immediately download the documents.
FDA 483 Sarepta Therapeutics, Inc., Andover | 2023
Out-of-stock
Emmanuel Adu-Gyamfi
Biologics Form 483
FDA 483 Catalent Maryland, Inc., Harmans | 2023
Out-of-stock
Emmanuel Adu-Gyamfi
Biologics Form 483
FDA 483 BioMarin Pharmaceutical Inc., Novato | 2022
Out-of-stock
Emmanuel Adu-Gyamfi
Biologics Form 483
FDA 483 Uniqure Inc, Lexington | 2022
Out-of-stock
Emmanuel Adu-Gyamfi
Biologics Form 483
Co-Investigators (16)
- Scott T. Ballard, FDA Investigator
- Sukyoung Sohn, FDA Investigator
- Viviana R. Ramirez, FDA Investigator
- Grace I. Cortesini, FDA Investigator
- Kevin J. Matthews, FDA Investigator
- Christine Harman, FDA Investigator
- Ou Ma, FDA Investigator
- Lilia L. Bi, FDA Investigator
- Thomas R. Withers, FDA Investigator
- Laura Fontan, FDA Investigator
- Andrew W. Harmon, FDA Investigator
- Kula N. Jha, FDA Investigator
- Unnee Ranjan, FDA Investigator
- Christian Lynch, FDA Investigator
- Alifiya H. Ghadiali, FDA Investigator
- Anurag Sharma, FDA Investigator